Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

By Reuters News

Sept 22 (Reuters) - Otsuka Pharmaceutical and Ionis Pharmaceuticals IONS.O said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis, or ALS.

Here are more details:

  • Otsuka's ulefnersen improved function and survival compared with placebo in patients with FUS-ALS, a rare inherited form of the disease that damages nerve cells controlling movement.

  • There are currently no approved treatments specifically targeting the genetic cause of FUS-ALS.

  • The drug also reduced markers linked to nerve cell damage and delayed disease progression.

  • Most side effects were mild or moderate, and the companies said the drug showed a favorable safety profile.

  • Otsuka and Ionis plan to discuss the results with the US FDA and other health authorities globally as they pursue potential accelerated approval pathways.

  • FUS-ALS causes progressive muscle weakness that can leave patients unable to move, speak, swallow or breathe independently.

  • Otsuka's ulefnersen is an experimental medicine designed to reduce production of the FUS protein linked to the disease.

  • Separately, Otsuka launched a global early access program for eligible FUS-ALS patients who cannot participate in clinical trials, allowing physicians to request access to ulefnersen before any potential approval.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.